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        Severe sepsis is a systemic host response to mi  cro-
bial infection, and mortality of severe sepsis 
patients reaches 30 –  50%. Recombinant activated 
protein C (APC) is the only approved drug that 
reduces mortality of adult severe sepsis patients. 
Recombinant APC resembles an endogenous 
plasma serine protease with pleiotropic eff  ects 
on coagulation, fi  brinolysis, infl  ammation, im-
mune cells, and vascular endothelial cells (for 
review see references   1  –  3  ). The antiapop-
totic, antiinfl  ammatory, and vascular perme-
ability eff  ects of APC are mediated through 
engagement of the endothelial cell protein C 
receptor (EPCR/  procr  ) and secondary activation 
of the G protein  –  coupled thrombin receptor, 
protease-activated receptor 1 (PAR1/F2R) by 
the APC  –  EPCR complex (  4  –  9  ). In contrast, 
the anticoagulant activity of APC is caused by 
receptor-independent proteolytic inactivation 
of coagulation factor Va. The anticoagulant 
eff  ect associated with APC therapy increases the 
risk of severe bleeding in septic patients, which 
imposes an upper limit on the dose of APC 
administered. In addition, APC is not eff  ective 
in children or in adults with less than severe 
sepsis (  10  –  12  ). The key mechanisms mediating 
the protective eff  ect of APC in severe sepsis are 
unclear. It is thought that the effi   cacy of APC 
is caused by the combination of its anticoagu-
lant and cell signaling activities. APC-mediated 
anticoagulation and promotion of fi  brinoly-
sis may reduce thrombotic organ damage and 
perfusion insuffi   ciency associated with severe 
sepsis, as well as suppress the infl  ammation-
  enhancing eff  ect of activated coagulation factors. 
The EPCR- and PAR1-dependent signaling 
activity of APC may enhance the viability of 
lymphocytes and endothelial cells, prevent the 
deterioration of the microvascular permeabil-
ity arrier associated with sepsis, and blunt the 
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  Activated protein C (APC) reduces mortality of severe sepsis patients but increases the risk 
of serious bleeding. APC exerts anticoagulant activity by proteolysis of factors Va/VIIIa. APC 
also exerts antiinfl  ammatory and antiapoptotic effects and stabilizes endothelial barrier 
function by APC-initiated cell signaling that requires two receptors, endothelial cell protein 
C receptor (EPCR) and protease-activated receptor 1 (PAR1). The relative importance of 
APC  ’  s various activities for effi  cacy in sepsis is unknown. We used protein engineering of 
mouse APC and genetically altered mice to clarify mechanisms for the effi  cacy of APC in 
mouse sepsis models. Mortality reduction in LPS-induced endotoxemia required the enzy-
matic active site of APC, EPCR, and PAR-1, highlighting a key role for APC  ’  s cytoprotective 
actions. A recombinant APC variant with normal signaling but      10% anticoagulant acti-
vity (5A-APC) was as effective as wild-type APC in reducing mortality after LPS challenge, 
and enhanced the survival of mice subjected to peritonitis induced by gram-positive or 
-negative bacteria or to polymicrobial peritoneal sepsis triggered by colon ascendens stent 
implantation. Thus, APC  ’  s effi  cacy in severe sepsis is predominantly based on EPCR- and 
PAR1-dependent cell signaling, and APC variants with normal cell signaling but reduced 
anticoagulant activities retain effi  cacy while reducing the risk of bleeding. 2440 NON-ANTICOAGULANT APC VARIANTS IN SEPSIS TREATMENT | Kerschen et al.
  To examine the eff  ects of APC treatment on endotoxin-
induced apoptosis and vascular permeability, cohorts of ani-
mals receiving an LD  50   dose of LPS concomitant with either 
10      g APC, 10      g S360A-APC, or carrier solution (PBS) 
were killed 24 h after induction of endotoxemia. At this time 
point,      90% of animals in all experimental groups were still 
alive, but death occurred shortly thereafter in the control 
groups treated with S360A-APC or only carrier (  Fig. 1 A  ). 
Treatment with APC, but not with S360A-APC, reduced 
the number of apoptotic cells in lung, spleen, and liver tissue 
sections, as detected by Tdt-mediated dUTP-biotin nick-end 
labeling (TUNEL) staining (  Fig. 2, A  –  G  ).   As confi  rmed in 
the liver, reduced apoptosis correlated with a suppression of 
caspase-3 activity in whole-tissue extracts (  Fig. 2 H  ). APC 
treatment also preserved vascular endothelial barrier func-
tion in the kidney, as demonstrated by measuring the perme-
ability of the vascular bed for fl  uorescent tracers of diff  erent 
molecular weights (MWs;   Fig. 2, I and J  ). This benefi  cial 
APC eff  ect was predominantly observed in small vessels (  Fig. 
2 K  ). Similarly, APC-treated animals exhibited signifi  cantly 
elaboration of proinfl  ammatory cytokine release by immune 
and endothelial cells. Results from animal studies and from 
clinical evaluation of other natural anticoagulants (i.e., anti-
thrombin [  13  ] and tissue factor pathway inhibitor [  12  ]) sug-
gest that the anti  coagulant activity of APC, which is the cause 
of bleeding complications, might not be absolutely necessary 
for its therapeutic effi   cacy in patients with severe sepsis. In 
this study, we distinguish the relative importance of antico-
agulation and receptor-dependent signaling via EPCR and 
PAR1 for APC  ’  s effi   cacy in reducing sepsis mortality. 
    RESULTS   
  Protective effect of APC in mouse endotoxemia 
  As an initial step to clarify the mechanisms by which APC 
reduces mortality in severe sepsis patients, we examined how 
APC therapy alters the outcome of mouse endotoxemia. 
When i.p. doses of LPS causing 50 or 90% mortality (LD  50   or 
LD  90  , respectively) were given to mice, recombinant mouse 
WT APC signifi  cantly reduced 7-d mortality (  Fig. 1, A and B  ).   
An i.v. bolus of APC was as eff  ective in reducing 7-d mortal-
ity as administration via a 20-min i.v. infusion of the same 
amount of APC. The recombinant mouse APC variant 
S360A-APC, which lacks proteolytic activity but retains 
some anticoagulant potency (  14  ), did not reduce mortality 
(  Fig. 1 A  ), showing that APC  ’  s enzymatic proteolytic activity 
is essential for mortality reduction. For LPS given at LD  90  , a 
single 10-     g APC dose reduced mortality from 90 to 30% 
(  Fig. 1 B  ), whereas for LPS given at LD  50  , single 10-     g (0.33 
mg/kg) or 2-     g (0.067 mg/kg) APC doses reduced mortality 
to      10% (  Fig. 1 A  ). 
  Figure 1.     APC reduces the mortality of LPS-induced endotoxemia. 
7-d survival of mice (  n     20 per group) infused with 10      g APC (    ), 2     g 
APC (  Δ  ), PBS (    ), or 10      g S360A-APC (   ;   n     10 per group) over a 20-min 
period before challenge with an LD  50   (A) or LD  90   (B) of LPS. The statistical 
signifi  cance of mortality and survival time was determined by the Kaplan-
Meyer log-rank test.     
    Table I.        Lymphocyte apoptosis using FITC-labeled 
caspase-3 antibody 
No LPS LPS LPS/APC
Spleen tissue
     T lymphocytes CD4    0.97        0.21 4.98       0.74*** 3.45       0.54
CD8    1.03        0.21 9.18       1.44*** 7.21       2.3
     B lymphocytes B220    0.83        0.32 4.8       0.82*** 3.07       1.32
     Granulocytes GR1    0.27        0.21 1.61       0.95* 2.08       0.84
Peripheral blood
     T lymphocytes CD4    0.3        0.2 8.19       1.67*** 5.61       1.94
CD8    0.46        0.3 9.14       9.42* 8.97       7.62
     B lymphocytes B220    0.6        0.33 19.4       11.7* 9.72       9.68
     Granulocytes GR1    0.01        0.01 0.24       0.29* 0.3       0.2
All collections were performed 24 h after LPS challenge and APC treatment . *, P      
0.05; and ***, P       0.001 compared with PBS control mice using the Student  ’  s   t   test.
    Table II.        Lymphocyte apoptosis using YO-PRO-1 
nuclear stain 
No LPS LPS LPS/APC
Spleen tissue
     T lymphocytes CD4    0.61        0.37 2.20       0.56** 4.57       3.48
CD8    1.36        0.72 4.44       1.01** 7.11       4.47
     B lymphocytes B220    1.24        0.07 6.42       0.88*** 7.43       5.17
     Granulocytes GR1    1.03        0.21 5.05       2.37* 7.61       3.93
Peripheral blood
     T lymphocytes CD4    0.23        0.06 1.69       0.66* 2.67       0.68
CD8    1.32        0.28 7.04       5.73* 14.4       10.2
     B lymphocytes B220    0.66        0.14 4.45       2.23* 5.04       2.71
     Granulocytes GR1    0.07        0.06 0.09       0.34 1.28       1.07
All collections were performed 24 h after LPS challenge and APC treatment . *, P      
0.05; **, P       0.01; and ***, P       0.001 compared with PBS control mice using the 
Student ’ s   t   test.JEM VOL. 204, October 1, 2007 
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  At 24 h after LPS administration, mean plasma levels of 19 
out of 23 assayed cytokines were somewhat lower in the APC-
treated group, and the putative eff  ects of APC treatment were 
found for IL-12p40/IL-12p70, IL-4, IL-5, Il-10, GM-CSF, 
G-CSF, IFN-     , and KC (Table S1). However, correction for 
multivariate testing rendered all diff  erences statistically nonsig-
nifi  cant. The eff  ects of APC on the early cytokine response 
to LPS were determined in additional cohorts of mice at 3 h 
after LPS challenge, and data were analyzed with respect to 7-d 
survival. For these comparisons, 8 out of 10 APC-treated mice 
and 1 out of 10 PBS-infused mice were 7-d survivors. A tenta-
tive correlation between treatment and survival was observed 
for changes in IL-12p40/IL-12p70, GM-CSF, IFN-     , IL-17, 
RANTES, and IL-5 (Table S2, available at http://www.jem
.org/cgi/content/full/jem.20070404/DC1), but correcting for 
multivariate testing rendered the diff  erences nonsignifi  cant. 
reduced lung infl  ammation, as determined by measurement 
of myeloperoxidase (MPO) activity in lung extracts (  Fig. 2 L  ). 
  LPS exposure caused activation of the coagulation and 
fi  brinolytic systems, platelet consumption, stimulation of in-
fl  ammatory cytokine responses, reduced numbers of circulat-
ing lymphocytes and monocytes, and increased numbers of 
granulocytes (Table S1, available at http://www.jem.org/cgi/
content/full/jem.20070404/DC1). Circulating immune cells 
exhibited increased evidence of apoptosis, as judged by caspase-3 
activation, and increased membrane permeability (  Fig. 3, 
A and B   and   Tables I and II  ).   Diff  erential blood cell counts; 
histo  pathology of lung, liver, and spleen (Fig. S1, A –  I); compo-
sition and abundance of immune cell populations in peripheral 
blood and spleen (Table S1); or the extent of lymphocyte 
apoptosis (  Fig. 3, A and B   and   Tables I and II  ) were not sig-
nifi  cantly aff  ected by treatment with APC or S360A-APC. 
  Figure 2.     APC treatment reduces apoptosis and LPS-induced vascular permeability. Nuclear HOECHST stain (A  –  C) and TUNEL assay (D  –  F) on liver 
sections of control mice (no LPS; A and D), LPS-challenged mice (B and E), and LPS-challenged mice treated with APC (C and F). (G) Quantitative analysis 
of apoptosis in liver, lung, and spleen tissue. (H) APC treatment reduces caspase-3 activity. All analyses were performed 24 h after LPS challenge. *, P      
0.05 using the Student  ’  s   t   test. (I) Vascular permeability was determined before (no LPS) or 8 h after LPS challenge by infusion of FITC-labeled high MW 
dextran and rhodamine-labeled low MW dextran. (J) Quantitation of rhodamine  –  dextran extravasation by morphometry. (K) Permeability barrier protec-
tion by APC occurs predominantly in smaller vessels. *, P       0.05 compared with LPS, as determined by the Student  ’  s   t   test. (L) MPO activity as a marker 
for neutrophil activity in lung tissue 24 h after LPS challenge. APC reduces lung infl  ammation. *, P       0.01 compared with PBS control lungs; and #, P       0.03 
compared with LPS challenged lungs, as determined by the Student  ’  s   t   test. Data represent the mean       SD of 10 randomly chosen fi  elds per section, with 
fi  ve sections per mouse and fi  ve mice each in the treatment and control groups. Bars, 100     m.   2442 NON-ANTICOAGULANT APC VARIANTS IN SEPSIS TREATMENT | Kerschen et al.
  At 24 h after LPS challenge, thrombin  –  antithrombin com-
plex (TAT) levels and platelet consumption in PAR1       /       and 
EPCR       /       mice were not diff  erent from those measured in 
WT mice (Table S3, available at http://www.jem.org/
cgi/content/full/jem.20070404/DC1).     D  -  dimer levels were 
signifi  cantly increased in EPCR       /       and PAR1       /       mice com-
pared with WT mice. APC treatment of EPCR       /      , but not 
of PAR1       /      , mice reduced     D  -  dimer levels to a similar extent 
seen for WT mice (Table S3). The cytokine profi  le of LPS-
challenged EPCR       /       mice at 24 h was similar to that of WT 
mice. Of note, APC treatment of LPS-challenged EPCR       /      , 
but not of PAR1       /      , mice elicited a highly signifi  cant 10- and 
7-fold augmentation of IL-6 and monocyte chemoattractant 
protein 1 levels, respectively (Table S3). 
  These results document that normal expression of EPCR 
and PAR1 is essential for mortality reduction by APC in 
mouse models of lethal endotoxemia. On the other hand, the 
reproducible prolongation of survival time in APC-treated 
PAR1       /       mice, which is not observed in EPCR       /       mice, 
indicates that some benefi  cial, EPCR-dependent eff  ects of APC 
do not require PAR1. 
  APC variants with reduced anticoagulant, but preserved 
signaling, function prevent endotoxemia mortality 
  The above observations (see previous section) demonstrate that 
EPCR and PAR1, and in extension the cell signaling activity 
of APC mediated by these receptors, are required for the abil-
ity of APC to reduce mortality. To determine whether this 
  In summary, APC reduces mortality in mouse models of 
lethal endotoxemia, diminishes the abundance of apoptotic 
cells in organs, and preserves the vascular permeability bar-
rier, and these benefi  cial eff  ects of APC require its proteolytic 
activity. On the other hand, we were not able to document 
a robust eff  ect of APC treatment on the plasma abundance of 
various infl  ammatory cytokines, or on the viability or com-
position and abundance of lymphocytes. 
  Therapeutic effi  cacy of APC requires functional EPCR 
and PAR1 
  To clarify the importance of the candidate receptors EPCR and 
PAR1 for the therapeutic effi   cacy of APC, the ability of APC 
to reduce LPS-induced mortality was determined in genetically 
altered mice, designated EPCR       /       mice, expressing greatly di-
minished amounts of EPCR (     10% of cell-surface expression; 
reference   15  ) and in knockout mice completely devoid of 
PAR1 (PAR1       /       mice) (  16, 17  ). Without APC treatment, the 
7-d mortality and survival time of PAR1       /       mice after chal-
lenge with an LD  50   of LPS were indistinguishable from those of 
WT mice. APC treatment of PAR1       /       mice challenged with 
an LD  50   of LPS reproducibly prolonged the time of survival 
(P   <   0.05) but did not aff  ect 7-d mortality (  Fig. 4 A  ).   Replicating 
earlier observations (  18  ), EPCR       /       mice displayed somewhat 
higher mortality (80%) in response to an LPS dose producing 
50% mortality in WT or PAR1       /       mice (  Fig. 4 B  ). Treatment 
of LPS-challenged EPCR       /       mice with APC did not alter the 
time of survival or 7-d mortality (  Fig. 4 B  ). 
  Figure 3.     APC effect on lymphocyte apoptosis. Representative ex-
ample of apoptosis detection in lymphocyte subpopulations as detected 
by FITC-labeled caspase-3 antibody (A), or double staining with YO-PRO-1 
and 7-AAD nuclear stains (B). Analysis was performed 24 h after adminis-
tration of LPS, PBS, or LPS and APC. Equivalent experiments were used to 
generate the data summarized in   Tables I and II  . APC does not reduce 
lymphocyte apoptosis. Numbers indicate the percentage of positive cells.     
  Figure 4.     Endotoxemia mortality reduction by APC requires EPCR 
and PAR1. (A) Survival of PAR1      /      mice  ( n     17 per group) infused with 
10      g APC (    ) or PBS (    ), followed LPS-challenge. APC treatment of 
PAR1              mice prolongs survival time (P       0.05). (B) Survival of mice (  n     
12 per group) with reduced EPCR function (EPCR      /     ) infused over 20 min 
with 10     g  APC  (   ) or PBS (    ), followed by LPS challenge. The statistical 
signifi  cance of mortality and survival time was determined by the Kaplan-
Meyer log-rank test.     JEM VOL. 204, October 1, 2007 
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was similar to its anticoagulant activity (  Fig. 5 B  ), because the 
major mechanism for APC-mediated profi  brinolytic activity in 
this assay involves inhibition of thrombin-dependent activa-
tion of thrombin-activatable fi  brinolysis inhibitor. 3K3A-APC 
and 5A-APC retained normal antiapoptotic activity in assays of 
staurosporine-induced apoptosis of endothelial cells (  Fig. 5 C  ), 
and 5A-APC exhibited normal antiinfl  ammatory activity in 
assays of LPS-stimulated TNF-      release (  Fig. 5 D  ). 
  The in vivo anticoagulant activity of APC variants was de-
termined by monitoring TAT levels after LPS-induced en-
dotoxemia. A 10-    g bolus of WT APC given simultaneously 
with LPS suppressed circulating TAT at 2 h; the same dose of 
5A-APC had no signifi  cant anticoagulant eff  ect, whereas 10      g 
of RR230/231AA-APC and 3K3A-APC showed intermediate 
pathway is not only necessary but also suffi   cient for APC  ’  s 
therapeutic effi   cacy, we tested the eff  ect of APC variants 
with greatly diminished anticoagulant activity but preserved 
receptor-mediated cytoprotective function on endotoxemia 
survival. Alanine substitutions in two surface loops of hu-
man APC diminish its anticoagulant activity while preserving 
EPCR- and PAR1-dependent direct eff  ects on cells (  19  ). 
In this case, corresponding variants of recombinant mouse APC 
were prepared: (a) 230/231-APC (RR230/231AA-APC), 
(b) 3K3A-APC (KKK192-194AAA-APC), and (c) 5A-APC 
(combining the RR230/231AA and KKK192-194AAA sub-
stitutions). These variants exhibited anticoagulant activities 
of 25, 33, and      8% of WT APC, respectively (  Fig. 5 A  ).   
The relative profi  brinolytic activity of each APC molecule 
  Figure 5.     Anticoagulant and cytoprotective activities of mouse APC variants. (A) Anticoagulant activity of recombinant mouse WT APC (    )  and 
APC variants (230/231-APC [  ◊  ], 3K3A-APC [    ], and 5A-APC [*]) determined in vitro in plasma. (B) Profi  brinolytic activity of WT APC (     ) and APC variants 
(230/231-APC [  ◊  ], 3K3A-APC [    ], 5A-APC [*], and S360A-APC [    ]). (C) Antiapoptotic activity of WT APC (     ) and APC variants (3K3A-APC [   ]  and  5A-APC 
[*]) in assays of staurosporin-induced (0.25      M, 24 h) mouse endothelial cell apoptosis. (D) Antiinfl  ammatory activity of WT APC (     ), WT protein C zymo-
gen (    ), and 5A-APC (*) induced in mouse Raw264.7 macrophage-like cells. Data represent the mean       SD. (E and F) APC effect on in vivo thrombin 
generation in endotoxin-challenged mice. Endotoxin-challenged mice (  n     6 per group) were infused with PBS (    ), 10 (    ) or 2 (   )      g WT APC, or APC 
variants, and thrombin generation was determined at 2 h (E) and at 30 min (F) after APC infusion by measuring plasma levels of TAT complex. Administra-
tion of 2      g 5A-APC did not signifi  cantly alter in vivo thrombin generation.     2444 NON-ANTICOAGULANT APC VARIANTS IN SEPSIS TREATMENT | Kerschen et al.
gered by live pathogens, i.e., i.p. infection with gram-positive 
  Staphylococcus aureus  , with gram-negative   Escherichia coli   O55:
B5 that was the source of the LPS preparations used in the 
endotoxemia models, and in a model of focal polymicrobial 
peritonitis with endogenous, fecal microorganisms triggered 
by colon ascendens stent implantation. 
  Administration of a single dose of either 10 or 2      g 5A-
APC immediately after infection with   S. aureus   did not alter 
survival time or overall mortality (  Fig. 7 A  ).   In contrast, two 
consecutive doses of 5A-APC administered 3 and 10 h after 
infection signifi  cantly reduced mortality (  Fig. 7 B  ). A compa-
rable reduction of mortality was achieved when the fi  rst of two 
doses was administered concomitant with bacterial inoculation 
(unpublished data). Corresponding results were obtained after 
infection with   E. coli  , as two consecutive 2-     g doses of 5A-
APC administered at the time of infection and 10 h thereafter 
signifi  cantly improved survival (  Fig. 7 C  ). Likewise, adminis-
tration of two consecutive 2-     g doses of 5A-APC 3 and 10 h 
after colon ascendens stent peritonitis (CASP) induction sig-
nifi  cantly improved survival (S360A-APC, 9 survivors; 5A-
APC, 17 survivors;   n   = 22 per group;   Fig. 7 D  ). 
  These data document that APC variants, such as 5A-
APC, with selectively reduced anticoagulant but near-
normal cell signaling potency reduce mortality associated 
with bacterial sepsis to a similar extent as in mouse models of 
LPS-induced endotoxemia. 
    DISCUSSION   
  Our studies imply that the cell signaling activities of APC, 
mediated by the receptors EPCR and PAR1, are much more 
important for APC  ’  s ability to reduce sepsis mortality than its 
anticoagulant activities. These fi  ndings may help resolve the 
debate about the controversial role of APC-initiated cell sig-
naling mechanisms in sepsis (  20  –  23  ). Based on mechanistic 
insights gained from the analysis of mouse endotoxemia, we 
provide proof of principle that a selective reduction of APC  ’  s 
anticoagulant activity by site-directed mutagenesis retains 
APC  ’  s effi     cacy in mortality reduction in endotoxemia, as 
well as in three diff  erent models of bacterial sepsis. The latter 
observation is consistent with the notion that the EPCR and 
PAR1 dependence of APC effi   cacy demonstrated for endo-
toxemia also plays a dominant role in mortality reduction in 
models of bacterial infection. 
  A fi  rst important implication of our fi  ndings is that vari-
ants such as 5A-APC may provide a safer alternative for the 
treatment of patients with severe sepsis by reducing the risk 
of severe bleeding associated with currently practiced APC 
therapy. Although our data strongly imply that the EPCR- 
and PAR1-mediated eff  ects of APC are both necessary and 
suffi   cient for mortality reduction in mouse models of endo-
toxemia and bacterial sepsis, human patients with severe sepsis 
and multiorgan failure may nevertheless benefi  t from antico-
agulation. In particular, in patients with sepsis complicated 
by disseminated intravascular coagulation, anticoagulation 
may reduce mortality risk and reduce morbidity secondary to 
thrombotic organ damage. The availability of variants such 
TAT reductions (  Fig. 5 E  ). A lower WT APC dose (2      g) 
markedly reduced TAT, whereas RR230/231AA-APC and 
3K3A-APC had intermediate anticoagulant eff  ects, and 5A-
APC had no anticoagulant eff  ect (  Fig. 5 E  ). Similar results 
were obtained when TAT was measured 30 min after admin-
istration of LPS and APC (  Fig. 5 F  ), indicating that the rela-
tive in vivo anticoagulant potency of APC variants mirrors 
their relative in vitro anticoagulant potency. 
  RR230/231AA-APC and the related variant, 5A-APC, 
were similarly eff  ective as WT APC in reducing LPS-induced 
mortality (unpublished data). Notably, 5A-APC at 10 or 2      g 
signifi  cantly reduced 7-d mortality (  Fig. 6 A  ), even when ad-
ministered as a single bolus 3 h after LPS challenge (  Fig. 6 B  ).   
  This suggests that a      10-fold reduction of APC antico-
agulant activity, while retaining its ability to engage EPCR and 
PAR1, does not eliminate APC  ’  s capacity to reduce mortality 
of endotoxemia; by extension, one may conclude that the 
interaction of APC with EPCR and PAR1 is not only essen-
tial but also suffi   cient to replicate the treatment benefi  t con-
veyed by normal, fully anticoagulant APC. 
  5A-APC prevents mortality of lethal bacterial sepsis 
  Experimental endotoxemia induced by LPS evokes some in-
fl  ammatory responses characteristic for bacterial sepsis, but 
the associated pathogenesis occurs entirely independent of 
the presence of the actual pathogen. We therefore examined 
whether the receptor-mediated eff  ects of 5A-APC are also 
suffi   cient to reduce mortality in three models of sepsis trig-
  Figure 6.     5A-APC reduces mortality of endotoxemia. (A) Survival of 
mice (  n     10 per group) that were infused with PBS (    , control), 10     g 
5A-APC (    ), or 2     g  (   ) 5A-APC for 20 min, followed by a 40-mg/kg i.p. 
injection of LPS. (B) Survival of mice (  n     10 per group) that were given a 
10-  μ  g i.v. bolus of 5A-APC (    ) or PBS (    ) 3 h after receiving 40 mg/kg 
LPS via i.p. injection. 5A-APC reduces mortality. The statistical signifi  cance 
of mortality reduction by APC treatment was determined by the Kaplan-
Meyer log-rank test.     JEM VOL. 204, October 1, 2007 
ARTICLE
2445
  The primary, successfully achieved objective of this study 
was to gain initial insight into the role of receptor-mediated 
APC eff  ects on sepsis survival. Accordingly, we chose 7-d 
mortality as the endpoint of our experimental analyses. A press-
ing, as yet unanswered question remains about the nature of 
the survival-enhancing downstream eff  ects triggered by APC 
through EPCR and PAR1. Although we document APC-
dependent alterations of coagulation, infl  ammation, apopto-
sis, and microvascular permeability in endotoxemia through 
premortem and survival analyses, it is unclear whether the 
observed changes can indeed account for the improved sur-
vival of APC-treated mice. For example, it appears doubtful 
whether the rather minor reduction of apoptotic cell abundance 
in tissue parenchyma suffi   ces to improve survival. In con-
trast to observations of reduced lymphocyte apoptosis in human 
patients undergoing APC therapy (  26  ), which could in theory 
explain the survival-promoting eff  ect of APC (  27  ), we were 
unable to correlate apoptosis or abundance of lymphocyte 
subpopulations with APC treatment or survival in mouse 
models. It remains to be determined whether this discrepancy 
is caused by species-specifi  c APC eff  ects, diff  erences between 
mouse endotoxemia and human sepsis, or dosing diff  erences. 
Likewise, with the exception of APC-treated EPCR-defi  cient 
mice, we only observed minor changes in the plasma cytokine 
profi  le and only moderate reductions of lung infl  ammation in 
APC-treated mice. The drastic APC-induced increase of IL-6 
and MCP-1 in EPCR-defi  cient mice might instead consti-
tute a nonphysiological, experimental artifact refl   ecting 
direct engagement of PAR1 by high bolus doses of APC. 
as 5A-APC, in which APC-mediated cell signaling activity 
required for mortality reduction and anticoagulant potency 
are dissociated, should enable the managing of APC infusion 
and anticoagulation as separate therapeutic entities, tailoring 
each to the specifi  c needs of a given patient. Second, com-
pared with normal APC, the effi   cacy of APC variants with 
selectively reduced anticoagulant activity likely can be ex-
plored in diff  erent modes of administration (i.e., continuous 
infusion vs. bolus) over a much greater dose range without 
a concomitant increase in associated bleeding risk. Indeed, 
although it was found that APC failed to protect septic chil-
dren and adult patients with less than severe sepsis, there was 
no attempt of dose optimization in these groups, providing a 
potential explanation for the lack of APC effi   cacy. The peak 
plasma concentrations of APC achieved by bolus injections 
in our experiments exceed by one to two orders of magni-
tude the level of APC maintained in septic patients by 96 h 
of continuous infusion (    45 ng/ml) (  24  ), approaching the 
plasma concentration of endogenous protein C. Because pro-
tein C zymogen and APC bind EPCR with comparable af-
fi  nity (  25  ), exogenously administered APC must outcompete 
endogenous protein C to engage EPCR. This may explain, 
on the one hand, why patients with low levels of endogenous 
protein C are most likely to benefi  t from APC therapy (  25  ); 
on the other hand, this suggests that engagement of EPCR 
is at best suboptimal under conditions currently established 
for APC therapy. Collectively, these considerations provide 
a strong rationale to reevaluate the optimal dose and mode of 
administration of APC and variants thereof in septic patients. 
  Figure 7.     5A-APC reduces mortality in bacterial sepsis. (A) Survival of mice (  n     10 per group) given either a 10-     g (    ) or 2-    g  (   ) i.v. bolus 
of 5A-APC or PBS (    , control), followed immediately by i.p. infection with 10  8    S. aureus  . (B) Survival of mice (  n     20 per group) given a 2-     g i.v. bolus of 
either 5A-APC (    ) or PBS (    , control) 3 and 10 h after i.p. infection with 10  8    S. aureus  . (C) Survival of mice (  n     20 per group) given a 2-    g  i.v.  bolus 
of either 5A-APC (    ) or PBS (    , control) at 3 and 10 h after i.p. infection with 2.5       10 8    E. coli   (O55:B5). (D) Survival of mice (  n     22 per group) after 
CASP. Mice were given a 2-     g i.v. bolus of either 5A-APC (    ) or S360A-APC (    ) at 3 and 10 h after CASP. The statistical signifi  cance of mortality 
reduction by APC treatment was determined by the Kaplan-Meyer log-rank test.     2446 NON-ANTICOAGULANT APC VARIANTS IN SEPSIS TREATMENT | Kerschen et al.
kines were measured using a 23-plex Bio-Plex system (Bio-Rad Laboratories) 
for mouse cytokines, with a reader (Illuminex 200; Bio-Rad Laboratories) and 
the Bio-Plex manager program (Bio-Rad Laboratories) for analysis. 
  Flow cytometry.     Flow cytometric analysis of spleen and peripheral blood cells 
for CD45, CD3, CD4, CD8, Mac-1, B220, Gr1, and NK1.1 was performed 
on a fi  ve-color fl  ow cytometer (LSRII; BD Biosciences) with fl  uorophor-
  conjugated antibodies (BD Biosciences). Before analysis, the cells were counted, 
and samples were adjusted to have the same cell number (2.5       10  7   cells). 
Analysis was performed using FACScan Diva software (BD Biosciences). 
  Histology.     Tissue was removed from the mouse without perfusion, placed 
in 10% neutral-buff  ered formalin solution, and embedded in paraffi   n. Micro-
photographs of hematoxylin and eosin  –  stained sections were captured using 
a microscope (Eclipse 600; Nikon) equipped with a digital camera (Spot 
Insight; Diagnostic Instruments) and analyzed with Spot advanced software 
(Diagnostic Instruments). 
  TUNEL assay.     Slides were deparaffi   nized by incubation overnight at 60  °  C, 
followed by xylene treatment. Tissue was hydrolyzed by nanopure water, 
followed by digestion with 40      g proteinase K. TUNEL assay was per-
formed using an in situ cell death detection kit (Roche), according to the 
manufacturer  ’  s directions. Tissue sections were counterstained with nuclear 
HOECHST stain. Images were captured with a fl  uorescent microscope (Ax-
ioskop; Carl Zeiss MicroImaging, Inc.) coupled to a SenSys camera (Roper 
Scientifi  c) and analyzed using Metamorph software (Molecular Devices). 
Analysis was performed on 10 randomly chosen fi  elds per section, with fi  ve 
sections per mouse and fi  ve mice each in the treatment and control groups. 
  Caspase-3 activity.     Caspase-3 protease activity in the liver was measured 
using a caspase-3 colorimetric assay kit (R  &  D Systems), according to the 
manufacture  ’  s instructions. In brief, whole liver was weighed and homoge-
nized in 1 ml of cell lysis buff  er. Homogenates were then centrifuged for 
1 min at 10,000   g  . The supernatant was incubated with Asp-Glu-Val-Asp-p-
nitroanilide (pNA) and reaction buff  er for 2 h at 37  °  C. Levels of the chromo-
phore pNA released by caspase-3 activity were spectrophotometrically 
quantifi  ed. The data were normalized for protein concentration. 
  Microvascular permeability.     Dextran infusion studies were performed as 
previously described (  30  ). In brief, FITC-labeled high MW dextran (MW   
200       10  4  , 100 mg/kg; Sigma-Aldrich) and rhodamine-labeled low MW 
dextran (MW   4       10  4  , 100 mg/kg; Sigma-Aldrich) were retroorbitally 
injected under 2.5% avertin anesthesia 8 h after LPS challenge. 15 min after 
dextran injection, the animals were killed, and heart, lungs, kidney, and 
liver were removed and immediately embedded in optimum cutting tem-
perature tissue freezing medium (Fisher Scientifi  c), frozen in liquid nitrogen, 
and stored at      80  °  C until further use. 10-     m tissue sections were cut and 
analyzed on a Nikon microscope equipped with a Spot Insight digital cam-
era, an ultraviolet light source, and fi  lters to visualize FITC and rhodamine 
fl  uorescence. All images were acquired with identical camera settings and 
exposure times. Measurements were made using ImageJ software (National 
Institutes of Health). 
  Measurement of apoptosis by fl  ow cytometry.     Flow cytometric analy-
sis of apoptosis on spleen and peripheral blood cells for CD4, CD8, CD25, 
B220, and Gr1 was performed as previous described (  31  ). In brief, samples 
were adjusted for cell number (5       10  5   cells) and stained with 250 nmol/liter 
YO-PRO-1 nuclear stain (Invitrogen) for 20 min in the dark, and 250 nM 
7-amino-actinomycin D (7-AAD; BD Biosciences) nuclear stain was added 
10 min before acquiring events. Together, these two stains distinguish early 
and late apoptotic cells from dead and live cells (  31  ). Cells stained with YO-
PRO-1 only were considered apoptotic. Cells stained by both YO-PRO-1 
and 7-AAD were considered dead. Intracellular caspase-3 was detected by 
fl  ow cytometry using FITC  –  anti  –  active caspase-3 mAb (BD Biosciences), as 
previously described (  31  ). 
We note that endothelial-associated EPCR has, at least in mice, 
the ability to sequester a stable pool of APC that is excluded from 
the circulation and accounts for approximately one third of the 
total APC pool (  28  ). Near absence of EPCR from endothelial 
cells may therefore lead (but only in EPCR-defi  cient mice) to a 
further increase of APC available for PAR1 interaction. APC 
modulation of     D  -  dimer follows a similar mouse strain  –  specifi  c 
pattern, with unknown underlying mechanism and relevance 
for survival. 
  The identifi  cation of EPCR and PAR1 as the necessary 
and suffi   cient mediators of APC  ’  s therapeutic benefi  t, as es-
tablished by this study, constitutes an essential fi  rst step toward 
the identifi  cation of the as yet elusive downstream eff  ects con-
trolled by this signaling pathway that are critical for survival. 
For example, the importance of the documented endothelial 
permeability barrier protection by APC for survival of en-
dotoxemia can be examined by testing 5A-APC effi   cacy in 
mice with endothelial cell  –  restricted loss of EPCR or PAR1 
function. Identifi  cation of the critical cell populations targeted 
by APC, characterization of APC eff  ects on this cell popula-
tion, validation of fi  ndings in models of bacterial sepsis, and 
hypothesis-based analysis of human patients will provide fur-
ther insight into the survival-enhancing function of APC. 
  MATERIALS AND METHODS 
  Animals.     C57BL/6 mice were obtained from Charles River Laboratories. 
Transgenic EPCR       /       and PAR1       /       male mice have been previously de-
scribed (  15  –  17  ). Animals used for this study had been backcrossed onto an 
inbred C57BL/6 background. All experiments involving animals were per-
formed in adherence to the National Institutes of Health guidelines on the 
use of laboratory animals and were approved by the Medical College of 
Wisconsin  ’  s Institutional Animal Care and Use Committee. 
  Chemicals and reagents.     Recombinant mouse APC, active site  –  mutant 
APC (S360A-APC), double-mutant APC (RR230/231AA-APC), and fi  ve-
point-mutant APC (5A-APC) were produced as previously described for 
human APC (  19  ). Heparin sodium salt and LPS (  E. coli   O55:B5) were pur-
chased from Sigma-Aldrich. 
  Infusion of APC.     8  –  12-wk-old C57BL/6 male mice were weighed to de-
termine the amount of LPS required to achieve a dose of 40 mg/kg. Mice 
were initially gas sedated in a plastic-enclosed chamber with isofl  urane-
soaked gauze. The mice were then placed supine with a nose cone and re-
ceived inhalation anesthesia 
  The femoral vein was aseptically exposed under inhalation anesthesia 
with 2% isofl  urane/oxygen through a 5-mm incision of the skin. A 0.6-mm 
(outer diameter) silicone catheter connected to a syringe injector was inserted 
into the vein and ligated in place. APC, APC variants, or vehicle (PBS) were 
infused at a rate of 9      l per minute for 20 min (180      l total). After infusion, 
the catheter was removed, the vein was closed by permanent ligation, and 
the skin wound was closed by suture. LPS was administered immediately 
thereafter via an i.p. injection. Alternatively, bolus doses of APC, APC vari-
ants, or PBS were administered through i.v. injection into the retroorbital 
venous plexus. 
  Analysis of hemostatic parameters and plasma cytokine levels.     Blood 
was obtained through a puncture of the vena cava 10 min after administration 
of 500 U heparin. Diff  erential blood analysis and platelet counts were deter-
mined in a counter (HEMAVET; Drew Scientifi  c). Plasma was prepared and 
stored at   −  80  °  C until use. TAT and     D  -  dimer were measured by ELISA 
(Enzygnost TAT Micro, Dade Behring;  d- di Asserachrome, Diagnostica Stago). 
Fibrinogen levels were measured by ELISA as previously described (  29  ). Cyto-JEM VOL. 204, October 1, 2007 
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  MPO activity assay.     MPO activity was measured as a marker of neutrophil 
activity within lung tissue, as previously described (  32  ). In brief, lungs were 
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partial thromboplastin time. Profi  brinolytic activity was measured in in vitro 
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Type Culture Collection). Cytotoxicity was determined by lactate dehydro-
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